BioMarin Pharmaceutical | BMRN - Assets


BioMarin Pharmaceutical reported $11.72B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 95.64B 3.14B Jun/2026
Bayer EUR 107.29B 659M Jun/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Insmed USD 2.23B 123.49M Sep/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
United Therapeutics USD 7.22B 505.9M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026